"Important reading for obstetrician-gynecologists and family physicians who provide obstetrical services."—New England Journal of Medicine
"Should be required reading in all law schools, and should be part of continuing education activities for judges and attorneys."—Judicature
From the Back Cover
Benedictin was prescribed to more than thirty-five million American women from its introduction in 1956 until 1983, when it was withdrawn from the market. The drug's manufacturer, Merrill Dow Pharmaceuticals, a major U.S. pharmaceutical firm, joined a list of other companies whose product liabilities would result in precedent-setting litigation. Before it was over, the Benedictin litigation would involve 2,000 claimants over a fifteen-year period. Michael D. Green offers a comprehensive overview of the Benedictin case and highlights many of the key issues in mass toxic substances litigation.